share_log

Star Lake BioscienceZhaoqing Guangdong's (SHSE:600866) Earnings Trajectory Could Turn Positive as the Stock Ascends 5.7% This Past Week

Star Lake BioscienceZhaoqing Guangdong's (SHSE:600866) Earnings Trajectory Could Turn Positive as the Stock Ascends 5.7% This Past Week

广东星湖生物科技(上海证券交易所股票代码:600866)的收益轨迹可能转为正值,因为该股上周上涨了5.7%
Simply Wall St ·  2024/02/10 07:36

The simplest way to benefit from a rising market is to buy an index fund. But if you buy individual stocks, you can do both better or worse than that. Unfortunately the Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (SHSE:600866) share price slid 36% over twelve months. That falls noticeably short of the market decline of around 22%. Longer term investors have fared much better, since the share price is up 1.0% in three years. Shareholders have had an even rougher run lately, with the share price down 24% in the last 90 days. But this could be related to the weak market, which is down 13% in the same period.

从市场上涨中获益的最简单方法是购买指数基金。但是,如果你买入个股,你的表现可能比这更好或更差。不幸的是,广东肇庆星湖生物科学有限公司(上海证券交易所代码:600866)的股价在十二个月内下跌了36%。这明显低于22%左右的市场跌幅。长期投资者的表现要好得多,因为股价在三年内上涨了1.0%。股东们最近的表现更加艰难,股价在过去90天中下跌了24%。但这可能与疲软的市场有关,同期市场下跌了13%。

The recent uptick of 5.7% could be a positive sign of things to come, so let's take a look at historical fundamentals.

最近上涨5.7%可能是即将发生的事情的积极信号,因此让我们来看看历史基本面。

There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

不可否认,市场有时是有效的,但价格并不总是能反映潜在的业务表现。研究市场情绪如何随着时间的推移而变化的一种方法是研究公司股价与其每股收益(EPS)之间的相互作用。

Unfortunately Star Lake BioscienceZhaoqing Guangdong reported an EPS drop of 29% for the last year. This proportional reduction in earnings per share isn't far from the 36% decrease in the share price. Given the lower EPS we might have expected investors to lose confidence in the stock, but that doesn't seemed to have happened. Rather, the share price is remains a similar multiple of the EPS, suggesting the outlook remains the same.

不幸的是,广东肇庆星湖生物科技有限公司报告称,去年每股收益下降了29%。每股收益的比例下降与股价下跌36%相差不远。鉴于每股收益较低,我们可能预计投资者会对该股失去信心,但事实似乎并非如此。相反,股价仍然是每股收益的相似倍数,这表明前景保持不变。

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

您可以在下图中看到 EPS 随时间推移的变化(点击图表查看确切值)。

earnings-per-share-growth
SHSE:600866 Earnings Per Share Growth February 9th 2024
上海证券交易所:600866 每股收益增长 2024 年 2 月 9 日

Dive deeper into Star Lake BioscienceZhaoqing Guangdong's key metrics by checking this interactive graph of Star Lake BioscienceZhaoqing Guangdong's earnings, revenue and cash flow.

查看这张广东星湖生物科学的收益、收入和现金流互动图表,深入了解广东星湖生物科学的关键指标。

A Different Perspective

不同的视角

We regret to report that Star Lake BioscienceZhaoqing Guangdong shareholders are down 36% for the year. Unfortunately, that's worse than the broader market decline of 22%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Longer term investors wouldn't be so upset, since they would have made 3%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. Before forming an opinion on Star Lake BioscienceZhaoqing Guangdong you might want to consider these 3 valuation metrics.

我们遗憾地报告,广东肇庆星湖生物科技股东今年下跌了36%。不幸的是,这比整个市场22%的跌幅还要严重。但是,可能只是股价受到了更广泛的市场紧张情绪的影响。如果有很好的机会,可能值得关注基本面。长期投资者不会那么沮丧,因为他们本可以在五年内每年赚3%。如果基本面数据继续显示长期可持续增长,那么当前的抛售可能是一个值得考虑的机会。在对广东星湖生物科学发表意见之前,你可能需要考虑这三个估值指标。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

当然,通过寻找其他地方,你可能会找到一笔不错的投资。因此,请看一下我们预计收益将增加的这份免费公司名单。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发